Market Overview

UPDATE: Stifel Nicolaus Initiates Abbott Laboratories at Buy Post Spin

Share:
Related ABT
Top Performing Industries For June 16, 2015
Mylan Offers Response to Abbott's Support for Perrigo Deal
Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog (Zacks)

Stifel Nicolaus initiated Abbott Laboratories (NYSE: ABT) with a Buy rating and a $40.00 price target.

Stifel Nicolaus commented, "Post-spin, we believe Abbott is now a balanced, diversified medical products company with an attractive, long-term outlook for mid-to-upper single-digit sales growth and low double-digit EPS growth. Although ABT currently trades at a premium to its peers, we see potential for further EPS upside over time, driven by an intensified focus on growth and margin enhancing initiatives. Using a sum-of-the-parts valuation framework, we arrive at a $40 target price."

Abbott Laboratories closed at $34.46 on Thursday.

Latest Ratings for ABT

DateFirmActionFromTo
Jun 2015BTIG ResearchInitiates Coverage onBuy
May 2015Evercore PartnersInitiates Coverage onBuy
May 2015Evercore ISIInitiates Coverage onBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters